Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients

Neha Korde, MD, Talib Dosani, Olga Simakova, PhD, Sham Mailankody, MD, Rene Costello, Mark Roschewski, MD, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, William D Figg, PharmD, Ola Landgren, MD PhD, Irina Maric, MD

Blood (2014) 124 (21): 2080.

https://doi.org/10.1182/blood.V124.21.2080.2080

Published: 2014

Journal Articles

Pretreatment Plasma Cell Proteasome Levels Predict Responses To Treatment With Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed By Lenalidomide Extended Dosing (CRd-R) In Newly Diagnosed Multiple Myeloma Patients

Irina Maric, MD, Olga Simakova, PhD, Neha Korde, MD, Adriana Zingone, MD, PhD, Rene Costello, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, George Carter, PA, Marcia Mulquin, RN, Diamond Zuchlinski, Mark Roschewski, MD, Ola Landgren, MD, PhD

Blood (2013) 122 (21): 1905.

https://doi.org/10.1182/blood.V122.21.1905.1905

Published: 2013

Journal Articles

Early Myelodysplastic Changes Present in Substantial Proportion of Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Patients

Neha Korde, MD, Qing Yan Liu, MD, Mary Kwok, MD, Elisabet E. Manasanch, MD, Olga Simakova, PhD, Sham Mailankody, Mark Roschewski, MD, Adriana Zingone, MD, PhD, Rene Costello, Diamond Zuchlinski, RN, Marcia Mulquin, RN, Katherine R Calvo, MD, PhD, Raul C. Braylan, MD, Irina Maric, MD, Ola Landgren, M.D., Ph.D.

Blood (2012) 120 (21): 1805.

https://doi.org/10.1182/blood.V120.21.1805.1805

Published: 2012

Journal Articles

Targeting the KIT Activating Switch Control Pocket: A Novel Mechanism to Inhibit Mast Cell Activation and KIT D816V Neoplastic Mast Cell Proliferation

Geethani Bandara, PhD, Yun Bai, MS, Eunice Ching Chan, PhD, Irina Maric, MD, Olga Simakova, PhD, Scott C. Wise, MS, Daniel Flynn, PhD, Dean D Metcalfe, MD, Alasdair M Gilfillan, PhD, Todd M Wilson, DO

Blood (2011) 118 (21): 1740.

https://doi.org/10.1182/blood.V118.21.1740.1740

Published: 2011

Journal Articles

Pure Red Cell Aplasia Associated with Plasma Cell Myeloma: Does Monoclonal Protein Inhibit Erythropoiesis?

Neha Korde, MD, Kelsey Loeliger, BA, Olga Simakova, PhD, Adriana Zingone, PhD, Richard Childs, MD, Ola Landgren, MD, PhD, Pierre Noel, MD, Elaine M Sloand, MD, Irina Maric, MD

Blood (2010) 116 (21): 642.

https://doi.org/10.1182/blood.V116.21.642.642

Published: 2010

Journal Articles

Carbon Nanotubes Activate Store Operated Calcium Entry (SOCE) In Human Platelets Manifested by STIM1 Capping

Silvia H. Lacerda, PhD, Jana Semberova, MD, Karel Holada, PhD, Olga Simakova, PhD, Jan Simak, PhD

Blood (2010) 116 (21): 3190.

https://doi.org/10.1182/blood.V116.21.3190.3190

Published: 2010

Journal Articles

Adverse Effects of Fullerenes on Endothelial Cells: Fullerenol C 60 (OH) 24 Induced Tissue Factor and ICAM-1 Membrane Expression and Caused Apoptosis In Vitro.

Monique P. Gelderman-Fuhrmann, PhD, Olga Simakova, PhD., Sheena F. Siddiqui, Alexander C. Vostal, Jan Simak, PhD

Blood (2006) 108 (11): 1801.

https://doi.org/10.1182/blood.V108.11.1801.1801

Published: 2006

NARROW

Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients

Pretreatment Plasma Cell Proteasome Levels Predict Responses To Treatment With Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed By Lenalidomide Extended Dosing (CRd-R) In Newly Diagnosed Multiple Myeloma Patients

Early Myelodysplastic Changes Present in Substantial Proportion of Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Patients

Targeting the KIT Activating Switch Control Pocket: A Novel Mechanism to Inhibit Mast Cell Activation and KIT D816V Neoplastic Mast Cell Proliferation

Pure Red Cell Aplasia Associated with Plasma Cell Myeloma: Does Monoclonal Protein Inhibit Erythropoiesis?

Carbon Nanotubes Activate Store Operated Calcium Entry (SOCE) In Human Platelets Manifested by STIM1 Capping

Adverse Effects of Fullerenes on Endothelial Cells: Fullerenol C 60 (OH) 24 Induced Tissue Factor and ICAM-1 Membrane Expression and Caused Apoptosis In Vitro.

Email alerts

ASH Publications

American Society of Hematology

Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients

Pretreatment Plasma Cell Proteasome Levels Predict Responses To Treatment With Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed By Lenalidomide Extended Dosing (CRd-R) In Newly Diagnosed Multiple Myeloma Patients

Early Myelodysplastic Changes Present in Substantial Proportion of Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Patients

Targeting the KIT Activating Switch Control Pocket: A Novel Mechanism to Inhibit Mast Cell Activation and KIT D816V Neoplastic Mast Cell Proliferation

Pure Red Cell Aplasia Associated with Plasma Cell Myeloma: Does Monoclonal Protein Inhibit Erythropoiesis?

Carbon Nanotubes Activate Store Operated Calcium Entry (SOCE) In Human Platelets Manifested by STIM1 Capping

Adverse Effects of Fullerenes on Endothelial Cells: Fullerenol C 60 (OH) 24 Induced Tissue Factor and ICAM-1 Membrane Expression and Caused Apoptosis In Vitro.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only